World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
62
Citations
25802
World Ranking
3088
National Ranking
1446

Overview

Cameron J. Turtle is affiliated with the Fred Hutchinson Cancer Research Center in the United States. Their research primarily focuses on medicine, with a significant emphasis on oncology and immunology, supported by substantial work in molecular biology, electrical and electronic engineering, and genetics.

The scientist's research contributions include numerous publications centered on CAR-T cell therapy, a specialized area within cancer treatment. Their main topics of work include:

  • CAR-T cell therapy research
  • Biosimilars and Bioanalytical Methods
  • Viral Infectious Diseases and Gene Expression in Insects
  • Virus-based gene therapy research
  • Advancements in Semiconductor Devices and Circuit Design
  • Lymphoma Diagnosis and Treatment
  • Silicon Carbide Semiconductor Technologies

The volume of publications indicates an extensive involvement in oncology and immunology fields, with oncology accounting for the majority of their work, followed by immunology and molecular biology.

Cameron J. Turtle has collaborated frequently with several researchers, notably:

  • Jordan Gauthier
  • David G. Maloney
  • Alexandre V. Hirayama
  • Mazyar Shadman
  • Erik L. Kimble

The scientist has published extensively in well-recognized journals. The notable venues with multiple publications include:

  • Blood
  • Transplantation and Cellular Therapy
  • Blood Advances
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Journal for ImmunoTherapy of Cancer

Some recent representative papers by Cameron J. Turtle include:

  • "Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes," 2020, The Lancet Respiratory Medicine
  • "Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma," 2020, Blood Advances
  • "Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure," 2020, Blood
  • "Immunogenicity of CAR T cells in cancer therapy," 2021, Nature Reviews Clinical Oncology
  • "Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy," 2020, Nature Communications

Best Publications

  • ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

    Daniel W. Lee;Bianca D. Santomasso;Frederick L. Locke;Armin Ghobadi

  • CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

    Cameron J. Turtle;Laïla Aïcha Hanafi;Carolina Berger;Theodore A. Gooley

  • Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells

    Harlan S. Robins;Paulo V. Campregher;Santosh K. Srivastava;Abigail Wacher

  • Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

    Juliane Gust;Kevin A. Hay;Kevin A. Hay;Laïla-Aïcha Hanafi;Daniel Li

  • Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells

    Cameron J. Turtle;Cameron J. Turtle;Laila-Aicha Hanafi;Carolina Berger;Carolina Berger;Michael Hudecek

  • Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.

    Kevin A. Hay;Kevin A. Hay;Laïla-Aïcha Hanafi;Daniel Li;Juliane Gust

  • Chimeric antigen receptor-modified T cells derived from defined CD8 + and CD4 + subsets confer superior antitumor reactivity in vivo

    Daniel Sommermeyer;Michael Hudecek;Michael Hudecek;Paula L. Kosasih;Tea Gogishvili

  • Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.

    Daniel E Leisman;Daniel E Leisman;Daniel E Leisman;Lukas Ronner;Lukas Ronner;Rachel Pinotti;Matthew D Taylor;Matthew D Taylor

  • Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

    Rebecca Gardner;David Wu;Sindhu Cherian;Min Fang

  • Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib

    Cameron J. Turtle;Kevin A. Hay;Laïla-Aïcha Hanafi;Daniel Li

  • HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells

    German G. Gornalusse;Roli K. Hirata;Sarah E. Funk;Laura Riolobos

  • Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy

    Joshua A. Hill;Joshua A. Hill;Daniel Li;Kevin A. Hay;Kevin A. Hay;Margaret L. Green;Margaret L. Green

  • Overlap and Effective Size of the Human CD8+ T Cell Receptor Repertoire

    Harlan S. Robins;Santosh K. Srivastava;Paulo V. Campregher;Cameron J. Turtle

  • Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.

    Marcelo C. Pasquini;Zhen-Huan Hu;Kevin Curran;Theodore Laetsch

  • Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.

    Kevin A. Hay;Kevin A. Hay;Jordan Gauthier;Alexandre V. Hirayama;Jenna M. Voutsinas

  • The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.

    Michael Hudecek;Michael Hudecek;Thomas M. Schmitt;Sivasubramanian Baskar;Maria Teresa Lupo-Stanghellini

  • HLA engineering of human pluripotent stem cells.

    Laura Riolobos;Roli K. Hirata;Cameron J. Turtle;Cameron J. Turtle;Pei Rong Wang;Pei Rong Wang

  • The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.

    Alexandre V. Hirayama;Jordan Gauthier;Kevin A. Hay;Kevin A. Hay;Jenna M. Voutsinas

  • Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells

    Ana Cordeiro;Evandro D. Bezerra;Alexandre V. Hirayama;Joshua A. Hill;Joshua A. Hill

  • Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure.

    Jordan Gauthier;Jordan Gauthier;Alexandre V. Hirayama;Janaki Purushe;Kevin A. Hay;Kevin A. Hay

Frequent Co-Authors

David G. Maloney
David G. Maloney Fred Hutchinson Cancer Research Center
Stanley R. Riddell
Stanley R. Riddell University of Washington
Hans Peter Kiem
Hans Peter Kiem Fred Hutchinson Cancer Research Center
Michael C. Jensen
Michael C. Jensen Seattle Children's Hospital
Edus H. Warren
Edus H. Warren Fred Hutchinson Cancer Research Center
Ted Gooley
Ted Gooley Fred Hutchinson Cancer Research Center
Brent L. Wood
Brent L. Wood University of Washington
Michael Boeckh
Michael Boeckh Fred Hutchinson Cancer Research Center
Derek N.J. Hart
Derek N.J. Hart University of Sydney
David N. Fredricks
David N. Fredricks University of Washington

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in expanding their expertise in Immunology through healthcare professions, pursuing advanced nursing degrees online presents a valuable option. Programs like the best pmhnp programs offer strong clinical placement rates, ensuring students gain essential hands-on experience in psychiatric mental health nursing.

Cost is often a significant consideration. Fortunately, there are cheapest psychiatric nurse practitioner programs available that provide quality education without burdening students with excessive debt.

Career advancement with a Doctorate in Nursing Practice (DNP) often leads to higher earning potential. To understand the financial benefits, reviewing the doctorate in nursing salary landscape offers crucial insights into where job opportunities are most lucrative across the USA.

Additionally, nurses looking to specialize further can explore bridging programs. The fnp to acute care np bridge program is an excellent pathway for Family Nurse Practitioners aiming to transition into acute care roles, expanding their clinical scope and career options.

Best Scientists Citing Cameron J. Turtle

Trending Scientists

Recently Published Articles